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Objective: Three genetic mutations have been associated with an increased risk of thromboembolic events: factor V Leiden
R506Q, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T (MTHFR) mutations. The aim of this
study was to determine the effect of these mutations on patency of peripheral bypass procedures and preoperative and
postoperative thromboembolic events.
Methods: Two hundred forty-four randomly selected volunteers participating in the Veterans Affairs Cooperative Study
#362 were tested for factor V Leiden, prothrombin, or MTHFR mutations with polymerase chain reaction. Patients
enrolled in the study were randomized to receive aspirin therapy or aspirin and warfarin therapy after a peripheral bypass
procedure. The frequencies of preoperative and postoperative thromboembolic events and primary patency (PP), assisted
primary patency (APP), and secondary patency (SP) rates were compared among carriers of the various mutations.
Results: Fourteen patients (5.7%) were heterozygous for the factor V Leiden mutation, seven (2.9%) were heterozygous
for the prothrombin mutation, and 108 (44.6%) were heterozygous and 15 (6.2%) homozygous for the MTHFR
mutation. After surgery, patients homozygous for the MTHFR gene mutation had increased graft thrombosis, compared
with patients who were heterozygous (33.3% versus 11.1%; P  .01), and lower PP, APP and SP rates (P < .05).
Furthermore, patients heterozygous for the MTHFR mutation had fewer graft thromboses (11.1% versus 24.4%; P 
.01), fewer below-knee amputations (0.9% versus 7.6%; P  .02), and higher PP, APP, and SP rates (PP, 79.6%; APP,
88.9%; SP, 90.7%; P < .05) compared with wild-type control subjects (PP, 63%; APP, 75.6%; SP, 76.5%; P < .05).
Conclusion: Patients with either factor V Leiden or prothrombin mutations were not at an increased risk for postoperative
graft occlusion or thromboembolic events. Patients heterozygous for MTHFR mutation had a lower risk of graft
thrombosis and higher graft patency rates compared with both homozygous and wild-type control subjects. Patients
homozygous for the MTHFR mutation had lower graft patency rates compared with patients who were heterozygous,
and a trend was seen toward lower patency rates compared with wild-type control subjects. Therefore, screening for the
MTHFR gene mutation before surgery may identify patients at an increased risk of graft thrombosis. (J Vasc Surg 2002;
36:1198-206.)
Thromboembolic events, most commonly in the form
of deep venous thrombosis (DVT), pulmonary embolism,
myocardial infarction (MI), or stroke, cause considerable
yearly mortality and morbidity.1,2 Currently, effective
forms of therapy are directed toward anticoagulation ther-
apy, thrombolysis, or circumvention of the occluded vascu-
lar segment through arterial reconstruction. However, a
significant number of coronary artery and peripheral artery
bypass grafts fail because of early thrombotic occlusion.3,4
The ability to identify patients at increased risk of graft
thrombosis could significantly alter their management and
hopefully improve their outcome.
In the past decade, our knowledge about the genetic
polymorphisms that predispose patients to thrombosis has
expanded. Currently, the most common genetic cause of a
prothrombotic phenotype is the factor V Leiden mutation
in which one nucleotide change at position 1691 of the
gene results in the substitution of adenine for guanine in
the structure of factor V.5,6 This mutation results in a delay
in the inactivation of activated factor V.5 It is present in
approximately 5% of the US population and increases the
risk of venous thrombosis three-fold to eight-fold for het-
erozygous carriers7-10 and 80-fold for homozygous carri-
ers.8 The factor V Leiden mutation also has been linked to
a variety of arterial events.11-13 The second most common
genetic cause of thrombophilia is a mutation in the pro-
thrombin gene, resulting in excess circulating levels of
serum prothrombin (factor II).14 This single point muta-
tion in the 3 untranslated region of the prothrombin gene
(on chromosome 11) at nucleotide 20210 is present in 2%
of the general population and confers an odds ratio (OR) of
thrombosis of 2.1 to 2.8.7,14,15 Furthermore, a single point
mutation in the methylenetetrahydrofolate reductase
(MTHFR) gene has been described at nucleotide 677
involving a change of cytosine to thymine.16 Approxi-
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mately 45% of the general population is heterozygous for
the mutation, and only 10% are homozygous.17-19 De-
pending on the serum folate level and other factors, carriers
of the MTHFR mutation may manifest hyperhomocys-
teinemia.20 Hyperhomocysteinemia and the presence of
the MTHFR mutation itself have both been independently
shown to be risk factors for venous thrombosis, although
their role in arterial thrombosis remains controversial.21-25
Given the prevalence of these genetic polymorphisms in the
general population and their association with venous
thrombosis and less often with arterial thrombosis, the aim
of this study was to determine whether the existence of any
one of these genetic mutations would increase the risk of
graft thrombosis or postoperative thromboembolic events
in a patient population undergoing peripheral bypass pro-
cedures.
METHODS
Veterans Affairs Cooperative Study #362. This
study was a subset of the Veterans Affairs (VA) Cooperative
Study #362 that prospectively enrolled 831 patients under-
going arterial revascularization of the lower extremities
between October 1, 1991, and September 30, 1996. Pa-
tients were stratified into two arms: those receiving autol-
ogous vein (femoral-popliteal or femoral-tibial, femoral-
peroneal, or femoral-pedal bypass) or prosthetic grafts
(axillo-femoral-femoral, femoral-femoral, femoral-popli-
teal above-knee, or femoral-popliteal below-knee). All par-
ticipants were prospectively randomized to one of two
treatment groups that consisted of aspirin therapy (325
mg) or aspirin (325 mg) plus low-dose warfarin therapy
(prothrombin time, 1.2 to 1.5; or international normalized
ratio, 2 to 3). Treatment with aspirin was initiated before
surgery, and warfarin therapy was initiated on postoperative
day 1. Both agents were intended to be continued through-
out the duration of the study. All data were analyzed on an
intent-to-treat basis. The study was conducted at 15 med-
ical centers according to the program policies set forth in
the Guidelines for VA Cooperative Studies. All patients
signed an approved informed consent form for the VA
Cooperative Study #362.
The primary endpoint was the initial occlusion of the
vascular reconstruction.26 Additional endpoints were am-
putation, stroke, MI, major hemorrhage, and death. Signif-
icant intercurrent events, including hemorrhage, arterial
thromboembolic or occlusive events, and venous thrombo-
embolic events, were recorded. Patients with endpoints
were observed until death within the study period.
The mean follow-up period was 3 years, with a range of
2 to 6 years. All patients underwent clinical evaluation
during their hospitalization, in the immediate postopera-
tive period at 2 weeks, and every 3 months thereafter. Study
protocol forms were completed during the hospitalization
and at each outpatient visit. Graft patency was evaluated
with clinical examination of the pulses distal to the bypass
graft and with color-flow duplex scanning at each of the
follow-up visits. Bypass graft occlusion was confirmed with
either duplex scan or arteriographic evaluation. Primary
patency (PP) was defined as patency that was maintained
without any operative or angiographic manipulations to
extend patency, and assisted primary patency (APP) was
defined as patency maintained with remedial surgery or
angiographic technique to correct a defect, such as stenosis,
with the graft remaining patent.
Genetic analysis. Of the 831 patients enrolled into
VA Cooperative Study #362, blood samples from 244
volunteers consecutively evaluated in the postoperative pe-
riod from January 1, 1995, to March 31, 1996, were
collected and analyzed with polymerase chain reaction
(PCR) for factor V Leiden, prothrombin G20210A, or
MTHFR gene mutations. All 244 patients signed an addi-
tional approved informed consent form before the collec-
tion of the blood samples for the purposes of genetic
analysis.
Polymerase chain reaction. Testing for the factor V
Leiden mutation was performed as previously described by
Bontempo et al.6 Primers for prothrombin G20210A mu-
tation were designed to generate Taq I susceptible PCR
products for the wild-type allele: PTH-4 5-CAATA-
AAAGTGACTCTCATC-3 (20190-20209) and PTH-5
5-AGGTGGTGGATTCTTAAGTC-3 (20307-
20288).27 Primers for MTHFR C677T gene variant were
as described by Frosst et al16: CyF-1 5-TGAAGGAGAAG-
GTGTCTGCGGGA 3 and CyF-2 5-AGGACGGTGCG-
GTGAGAGTG-3. Amplification of 50 to 500 ng of
genomic DNA was performed in a 30-cycle PCR reaction
for each primer pair. Cycles consisted of denaturaton of
94° C for 15 seconds, annealing at 55° C for 15 seconds,
and extension at 72° C for 30 seconds in a 9600 Perkin
Elmer thermal cycler (Norwalk, Conn). PCR products
were electrophoresed on a neutral 3% agarose gel for in-
spection.
PTH-4 and PTH-5 amplify a 118-base pair (bp) frag-
ment of the gene encoding the prothrombin protein. The
118-bp fragment includes the G20210A transition site.
After Taq I treatment, the wild-type allele yields fragments
of 98-bp and 20-bp and the mutant allele that is not
susceptible to Taq I yields a 118-bp fragment. Repeat
testing of mutant alleles is routinely performed.
CyF-1 and CyF-2 amplify a 198-bp fragment of the
MTHFR gene containing the C677T transition site. Hinf I
digestion of a mutant allele yields fragments of 175 and 23
bp, and the wild-type allele is not susceptible to digestion
(198 bp). All extractions and amplifications were per-
formed in a molecular diagnostics facility. To ensure the
absence of amplicon contamination, water negative con-
trols were included in each test.
Thromboembolic variables. The association of these
mutations with several venous and arterial thromboembolic
events, and other atherosclerotic risk factors, was evaluated.
The preoperative variables evaluated included a history of
hypertension, diabetes mellitus, MI, transient ischemic at-
tack (TIA), reversible ischemic neurologic deficit, stroke,
current tobacco use, and any prior lower extremity ampu-
tations. After surgery, correlation was made to graft throm-
bosis, MI, TIA, stroke, ocular ischemic event, and DVT.
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PP, APP, and secondary patency (SP) rates were calculated
for all groups.
Statistics. Group differences for postoperative throm-
boembolic events were analyzed with the Fisher exact test,
two-tail. Group differences for patency rates were analyzed
with the Cox proportional hazards model. Independent
predictors were determined with Cox regression. The
Kaplan-Meier method was used in the construction of the
patency plots. Figures are represented as the mean  the
standard error. Significance was assumed at P values of less
than .05.
RESULTS
Gene polymorphism and patient demographics. Of
the 244 patients evaluated for this study, 14 (5.7%) were
heterozygous carriers of the factor V Leiden mutation and
seven (2.9%) were heterozygous carriers of the prothrom-
bin G20210A gene mutation. No patients who were ho-
mozygous for these mutations were encountered. One
hundred eight patients (44.6%) were heterozygous and 15
(6.2%) were homozygous for the MTHRF gene mutation
(Table I). All of the mutations were more frequent among
white than black patients. No age differences were seen
among the various mutation groups. Similarly, the inci-
dence rate of diabetes mellitus, hypertension, and tobacco
use was comparable among groups (Table I).
Preoperative thromboembolic events. No differ-
ences were found within the three gene polymorphisms and
a preoperative history of MI, reversible ischemic neurologic
deficit, or stroke (Table II). Heterozygous carriers of the
MTHFR mutation reported more TIA compared with
MTHFR wild-type control subjects (15% versus 2.5%; Ta-
ble II). Heterozygous carriers of the factor V Leiden mu-
tation reported more preoperative amputations compared
with factor V Leiden wild-type control subjects (37.5%
versus 13.9; Table II). No trend in type of amputation was
noted.
Postoperative thromboembolic events. Of the post-
operative thromboembolic events monitored, including
MI, TIA, ocular ischemic events, stroke, DVT, or pulmo-
nary embolism, no significant differences were seen within
mutation groups. However, a trend was seen toward graft
thrombosis with homozygous carriers of the MTHFR mu-
tation compared with the MTHFR wild-type and heterozy-
gous control subjects (Table III). Unexpectedly, heterozy-
gous carriers of the MTHFR gene mutation had
significantly less graft thrombotic events when compared
with both MTHFR homozygous and wild-type control
subjects (11.1% versus 33.3% and 24.4%, respectively; P 
.010; Table III). Moreover, heterozygous MTHFR carriers
were also less like to undergo below-knee amputation
compared with MTHFR wild-type control subjects (0.9%
versus 7.6%; P  .020).
Graft patency. Cumulative PP, APP, and SP rates,
with a mean follow-up period of 3 years, were determined
for all patients and were analyzed according to gene muta-
tion (Table IV). Overall, for the 244 patients in this study,
the PP rate was 69.7%, the APP rate was 81.1%, and the SP
rate was 82.4%. Analysis of patency rates with gene muta-
tion revealed statistically similar data with the exception of
carriers of the MTHFR mutation (Table IV and Fig).
Patients who were heterozygous had significantly higher
PP (79.6%), APP (88.9%), and SP (90.7%) rates compared
with both wild-type control subjects (63.0%; P  .019;
75.6%; P  .018; and 76.5%; P  .009, respectively) and
homozygous carriers (46.7%; P  .005; 66.7%; P  .021;
and 66.7%; P  .009, respectively). Homozygous carriers
of the MTHFR mutation had patency rates lower than
wild-type control subjects, but given the small number of
patients in this group, statistical significance was not
reached.
Primary patency, APP, and SP rates among the various
genetic make-ups were further analyzed according to study
arm and treatment group (Table V). Among the study
arms, the same pattern persisted when evaluating patients
who received prosthetic grafts. Patients with the heterozy-
gous MTHFR mutation had higher PP, APP, and SP rates
compared with both MTHFR homozygous and wild-type
control subjects. However, these differences were not ob-
served in patients with similar gene mutations receiving
autologous vein as their conduit (Table V). Analysis by
treatment group revealed that heterozygous carriers of the
MTHFR mutation who received aspirin therapy alone did
better than both MTHFR homozygote and wild-type con-
trol subjects with respect to PP, APP, and SP rates (Table
V). However, among patients with similar genetic muta-
Table I. Patient demographics by gene mutations
Preoperative variable
Factor V
heterozygote
Factor V
wild-type
Prothrombin
heterozygote
Overall* 14/244 (5.7%) 230/244 (94.3%) 7/239 (2.9%)
Race
Black 0/48 48/48 (100.0%) 0/47
White 14/196 (7.1%) 182/196 (80.3%) 7/192 (3.7%)
Hypertension 6/14 (42.9%) 125/230 (54.4%) 1/7 (14.3%)
Diabetes mellitus 2/14 (14.3%) 82/230 (35.7%) 2/7 (28.6%)
Current tobacco use 9/14 (64.3%) 135/230 (58.7%) 6/7 (85.7%)
Age (mean  standard error) 59.7  10.6 63.5  7.7 63.6  8.5
*Note: Overall also reflects six patients of other races.
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tions receiving both aspirin and warfarin therapy, patency
rates were similar across groups from improved patency in
the wild-type and homozygote cohorts (Table V).
To determine whether the lack of difference of patency
observed between the MTHFR gene mutation groups with
respect to the use of autologous vein or among those
patients receiving aspirin and warfarin therapy were from a
lack of power in our study given the small number of
patients in some of the groups, a power analysis was per-
formed. With respect to Table IV, to achieve a statistically
significant difference with a two-sided type I error of 0.05
and a power of 80% for the differences observed in APP, the
Table II. Preoperative thromboembolic events by gene mutation
Preoperative variable
Factor V
heterozygote
Factor V
wild-type
Prothrombin
heterozygote
Prothrombin
wild-type
MTHFR
heterozygote
MTHFR
homozygote
MTHFR
wild-type
MI 2 (14.3%) 50 (21.7%) 2 (28.6%) 49 (21.1%) 22 (20.4%) 3 (20.0%) 26 (21.9%)
TIA 1 (7.1%) 19 (8.3%) 1 (14.3%) 19 (8.2%) 16 (15.0%) 1 (6.7%) 3 (2.5%)
RIND 0 4 (1.8%) 0 4 (1.7%) 2 (1.9%) 1 (6.7%) 1 (0.8%)
Stroke 2 (14.3%) 26 (11.3%) 1 (14.3%) 26 (11.2%) 12 (11.1%) 1 (6.7%) 15 (12.6%)
Prior amputation* 5 (35.7%) 32 (13.9%) 2 (28.6%) 35 (15.1%) 14 (13.0%) 1 (6.7%) 22 (18.5%)
Above-knee 1 (7.1%) 5 (2.2%) 1 (14.3%) 5 (2.2%) 1 (0.9%) 0 5 (4.2%)
Below-knee 1 (7.1%) 4 (1.7%) 0 5 (2.2%) 2 (1.9%) 0 3 (2.5%)
Symes 0 0 0 0 0 0 0
Transmetatarsal 1 (7.1%) 3 (1.3%) 0 4 (1.7%) 1 (0.9%) 0 3 (2.5%)
Digit 1 (7.1%) 18 (7.8%) 1 (14.3%) 18 (7.8%) 6 (5.6%) 1 (6.7%) 12 (10.1%)
Other 1 (7.1%) 7 (3.0%) 0 8 (3.5%) 4 (3.7%) 0 4 (3.4%)
No. (total) 14 230 7 232 108 15 119
*Six patients had more than one amputation.
RIND, Reversible ischemic neurologic deficit.
Table III. Postoperative thromboembolic events by gene mutation
Postoperative variable
Factor V
heterozygote
Factor V
wild-type
Prothrombin
heterozygote
Prothrombin
wild-type
MTHFR
heterozygote
MTHFR
homozygote
MTHFR
wild-type
Graft thrombosis 4 (28.6%) 42 (18.3%) 2 (28.6%) 42 (18.1%) 12 (11.1%) 5 (33.3%) 29 (24.4%)
TIA 0 3 (1.3%) 0 3 (1.3%) 1 (0.9%) 0 2 (1.7%)
Stroke 0 22 (9.6%) 1 (14.3%) 21 (9.1%) 13 (12.0%) 0 8 (6.7%)
Ocular ischemic event 0 3 (1.3%) 0 3 (1.3%) 3 (2.8%) 0 0
MI 0 9 (3.9%) 0 9 (3.9%) 6 (5.6%) 1 (6.7%) 2 (1.7%)
DVT 0 1 (0.4%) 0 1 (0.4%) 1 (0.9%) 0 0
Venous thromboembolism 0 2 (0.9%) 0 2 (0.9%) 1 (0.9%) 0 1 (0.8%)
Amputation 2 (14.3%) 42 (18.3%) 0 44 (19.1%) 16 (14.8%) 4 (26.7%) 24 (20.3%)
Above-knee 2 (14.3%) 7 (3.1%) 0 9 (3.9%) 4 (3.7%) 2 (13.3%) 3 (2.5%)
Below-knee 0 11 (4.8%) 0 11 (4.8%) 1 (0.9%) 1 (6.7%) 9 (7.6%)†
Symes 0 0 0 0 0 0 0
Transmetatarsal 0 7 (3.1%) 0 7 (3.0%) 3 (2.8%) 0 4 (3.4%)
Digit 0 20 (8.7%) 0 20 (8.7%) 9 (8.3%) 2 (13.3%) 9 (7.6%)
Other 0 3 (1.3%) 0 3 (1.3%) 2 (1.9%) 0 1 (0.9%)
No. (total) 14 229 7 231 108 15 118
*P  .01 heterozygous versus wild-type.
†P  0.02 heterozygous versus wild-type.
Prothrombin
wild-type
MTHFR
heterozygote
MTHFR
homozygote
MTHFR
wild-type
232/239 (97.1%) 108/242 (44.6%) 15/242 (6.2%) 119/242 (49.2%)
47/47 (100.0%) 8/48 (16.7%) 0/48 40/48 (88.3%)
185/192 (96.4%) 100/196 (51.0%) 15/196 (7.7%) 79/196 (40.3%)
128/232 (55.2%) 56/108 (51.9%) 6/15 (40.0%) 68/119 (57.1%)
80/232 (34.5%) 37/108 (34.3%) 4/15 (26.7%) 42/119 (35.3%)
135/232 (58.2%) 64/108 (59.3%) 10/15 (66.7%) 69/119 (58.0%)
63.3  7.8 62.8  8.1 65.0  5.8 63.4  7.9
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following sample sizes would be necessary: heterozygote
versus homozygote, n 56; heterozygote versus wild-type,
n 122; and homozygote versus wild type, n 403. With
respect to Table V, for the differences observed in the
aspirin treatment group for APP, the following sample sizes
would be necessary to achieve a statistically significant
difference with a two-sided type I error of 0.05 and a power
of 80%: heterozygote versus homozygote, n  23; hetero-
zygote versus wild-type, n  35; and, homozygote versus
wild-type, n  258. With respect to Table V, for the
differences observed in the prosthetic study arm for APP,
the following sample sizes would be necessary to achieve a
statistically significant difference with a two-sided type I
error of 0.05 and a power of 80%: heterozygote versus
homozygote, n  31; heterozygote versus wild-type, n 
69; and homozygote versus wild-type, n  189. As such,
our study is underpowered because of the rarity of the
mutations and the small sample size in the groups positive
for the genetic aberration. All the differences should be
interpreted with caution.
DISCUSSION
Thrombosis of peripheral artery bypass grafts remains a
significant clinical concern. Approximately 40% of lower
extremity reconstructions fail by 4 years.28 Current thera-
peutic methods directed toward prevention of graft throm-
bosis involve antiplatelet therapy or anticoagulation ther-
apy or a combination of both. This, however, implies that
patients who are not at an increased risk of thrombosis are
treated along with those who are. The ability to identify
patients at increased risk of graft occlusion would be ben-
eficial because it would result in the treatment of only those
Life-table analysis of APP patency rates according to (A) MTHFR gene mutations, (B) treatment arm, and
(C) treatment group.
Table IV. Graft patency rate by gene mutation
Factor V
heterozygote
Factor V
wild-type P value
Prothrombin
heterozygote
Prothrombin
wild-type P value
MTHFR
heterozygote
MTHFR
homozygote
MTHFR
wild-type P value
PP 9 (64.3%) 161 (70.0%) .445 4 (57.1%) 164 (70.7%) .359 86 (79.6%) 7 (46.7%) 75 (63.0%) .005*
.019†
.139‡
APP 10 (71.4%) 188 (81.7%) .199 5 (71.4%) 190 (81.9%) .461 96 (88.9%) 10 (66.7%) 90 (75.6%) .021*
.018†
.268‡
SP 11 (78.6%) 190 (82.6%) .455 5 (71.4%) 193 (83.2%) .399 98 (90.7%) 10 (66.7%) 91 (76.5%) .009*
.009†
.233‡
No. (total) 14 230 7 232 108 15 119
*Heterozygote versus homozygote.
†Heterozygote versus wild-type.
‡Homozygote versus wild-type.
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patients who need anticoagulation, thereby limiting the
number of patients exposed to the risks associated with
anticoagulant therapy. Although our current knowledge of
the hypercoaguable state is expansive, our ability to predict
which patients are more prone to have postoperative graft
occlusion remains limited. Genetic studies have revealed
the existence of multiple mutations that are associated with
an increased risk of thrombotic events mostly in the venous
system (review7,29). Their role if any in arterial bypass
failure has never been accurately described. The mere pres-
ence of such a genetic mutation and a hypercoaguable state
also does not necessarily imply a benefit from postoperative
anticoagulation therapy. The aim of this study was to
determine whether patients who are carriers of factor V
Leiden, prothrombin G20210A, or MTHFR gene muta-
tions were at an increased risk of postoperative thrombo-
embolic events or graft thrombosis.
The factor V Leiden mutation was first described in
1994 in association with resistance to activated protein C
and is present in approximately 5% of the US population.5
Since the original description, it is now widely accepted as a
major risk factor for the development of venous thrombo-
sis. Approximately 40% to 60% of patients with a history of
familial thrombophilia are carriers of the factor V Leiden
mutation, and it is also present in 20% of patients with
spontaneous DVT for the first time.30 Its role in arterial
thrombosis, however, is controversial. Most large-scale
evaluations found no increased prevalence of the factor V
Leiden gene mutation among patients with arterial dis-
ease.10 Smaller studies, however, have associated the mu-
tation with arterial thromboembolic events. Moor et al12
found that the factor V mutation tended to be associated
with early saphenous vein graft occlusion after coronary
artery bypass grafting (P .06), and our group11 found an
association between the factor V Leiden mutation and the
development of arterial thromboembolic events (MI and
stroke).
The association of the factor V Leiden mutation with
peripheral vascular disease is less well characterized.
Donaldson et al13 concluded that the presence of the factor
V mutation was associated with early cerebrovascular events
and late graft thrombosis (P  .030). However, Foley et
al31 reported a prevalence of the factor V Leiden mutation
in patients with peripheral vascular disease of 17.8%, which
is much higher than the 3.5% in the United Kingdom
population. But they failed to identify an association with
graft occlusion after arterial reconstruction. Our current
data found no increase in the prevalence of the factor V
Leiden mutation in patients with severe peripheral vascular
disease and no association with postoperative graft failures.
The patient populations studied may explain the differences
among the various reports. Each patient population has its
own preexisting diseases and independent risk factors for
thromboembolic events, resulting in different risks for
thrombosis. Screening for the factor V Leiden mutation
would thus be of little benefit in this context.
The body of literature on the prothrombin G20210A
gene mutation is much less extensive than that on the factor
V Leiden mutation. Originally described in 1996, this less
frequent genetic mutation has also been established as a risk
factor for venous thromboembolisms.14 Although its prev-
alence in the general population is 2%, it is found in 6.2% of
patients with DVT and in 18% of patients with a family
history of thrombophilia.14,32 Similar to factor V Leiden
mutation, its role in arterial thromboembolism is less well
established. The studies evaluating the association between
the prothrombin G20210A gene mutation and arterial
thromboembolism are few. They have linked the gene to an
increased risk of MI32 and cerebral infarction.33 Other
reports found no increased risk of arterial thrombosis.34
These studies are limited in number and have small patient
enrollments. Our data revealed a prevalence in patients with
severe peripheral vascular disease similar to the general
population and no clear effect on graft thrombosis or
arterial events. With the rarity of the mutation, and until
additional data are encountered, screening for this gene in
association with arterial reconstruction would not be use-
ful.
The role of the MTHFR gene mutation in venous and
arterial thrombosis is much more complex. The presence of
the MTHFR mutation has been associated with high serum
homocysteine levels in some studies but not in oth-
ers.18,19,35-37 It has been postulated that the serum folate
level, in addition to other factors, may determine whether
the MTHFR mutation will manifest itself with high or
normal homocysteine levels.20 Hyperhomocysteinemia has
been independently associated with an increased risk of
venous thrombosis, and its role in arterial thrombosis and
coronary artery disease remains debatable.21-25 Because not
all patients with the MTHFR mutation have high homo-
cysteine levels, and not all patients with high homocysteine
levels have MTHFR mutations, and because there are many
other causes of hyperhomocysteinemia, much remains to
be learned about this genetic mutation. Although a pleth-
ora of studies has evaluated hyperhomocysteinemia and
thromboembolic events, few studies have analyzed the
association of the genetic mutation with an increased risk of
thrombosis. To our knowledge, the relative importance of
the heterozygous MTHFR mutation has not been docu-
mented before. We noted that heterozygous carriers of the
MTHFR gene mutation actually had less graft thrombosis,
higher patency rates, and fewer below-knee amputations. If
this finding were corroborated with additional studies, it
would be reasonable to speculate that the gene in a het-
erozygous state actually confers a survival benefit, resulting
in a selection bias with propagation of the gene. This would
explain the relatively high prevalence of this mutation. The
heterozygote state may also be a marker of a yet unidenti-
fied biochemical or physiologic change that is protective
against thrombus formation.
We also observed a trend in the homozygous carriers of
the MTHFR mutation toward more graft thromboses and
lower patency rates. However, this trend failed to reach
statistical significance possibly because of the small number
of patients with this particular mutation. A larger cohort of
patients may reveal a significant association between the
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presence of the homozygote mutation and an increased risk
of graft thrombosis.
In this study, we compared the patency rates within the
different gene mutation groups for the different treatment
groups and study arms. We did not find a statistically
significant difference among the MTHFR gene mutation
populations with respect to patency with warfarin therapy
or a vein conduit. One potential explanation for this pattern
in the data could be a type I error from overanalysis of the
data through multiple statistical comparisons. A larger pro-
spective study would be necessary to confirm or refute these
data. Furthermore, although multiple statistical compari-
sons were made with the data in this manuscript, large
enough sample sizes did not exist for most of the gene
mutation groups to achieve 80% power. The intent of this
study was not to definitively determine the predictive value
of the presence of these gene mutations with respect to
graft patency. Rather, the intent was to determine whether
a relationship existed that would be worth pursuing with
further investigations.
Another shortcoming of this study was the limited
number of patients with more than one mutation. Because
only nine such patients existed in our study, an analysis of
the effect of multiple mutations with respect to patency and
graft occlusion was not possible. In a study by Salomon et
al,38 the presence of one, two, or three of these gene
mutations was evaluated for the prevalence and thrombotic
risk associated with these prothrombotic gene polymor-
Table V. Patency rate by treatment group/study arm
Factor V
heterozygote
Factor V
wild-type P value
Prothrombin
heterozygote
PP by treatment group
Aspirin 4/6 (66.7%) 76/109 (69.7%) .300 2/5 (40.0%)
Aspirin  warfarin 5/8 (62.5%) 85/121 (70.3%) .691 2/2 (100.0%)
PP by study arm
Prosthetic 5/7 (71.4%) 88/118 (74.6%) .535 3/4 (75.0%)
Vein 4/7 (57.1%) 73/112 (65.2%) .575 1/3 (33.3%)
APP by treatment group
Aspirin 4/6 (66.7%) 85/109 (78.0%) .276 3/5 (60.0%)
Aspirin  warfarin 6/8 (75.0%) 103/121 (85.1%) .326 2/2 (100.0%)
APP by study arm
Prosthetic 5/7 (71.4%) 91/118 (77.1%) .471 3/4 (75.0%)
Vein 5/7 (71.4%) 97/112 (86.6%) .214 2/3 (66.7%)
SP by treatment group
Aspirin 4/6 (66.7%) 85/109 (78.0%) .276 3/5 (60.0%)
Aspirin  warfarin 7/8 (87.5%) 105/121 (86.8%) .859 2/2 (100.0%)
SP by study arm
Prosthetic 6/7 (85.7%) 92/118 (78.0%) .920 3/4 (75.0%)
Vein 5/7 (71.4%) 98/112 (87.5%) .182 2/3 (66.7%)
*Heterozygote versus homozygote.
†Heterozygote versus wild-type.
‡Homozygote versus wild-type.
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phisms. Patients with a single mutation in the factor V gene
were at the highest risk of venous thrombosis (OR, 16.3),
followed by the prothrombin G20210A gene mutation
(OR, 3.6) and the MTHFR gene mutation (OR, 2.1). With
two mutations, possession of both the factor V and pro-
thrombin mutations increased the OR to 58.6. The pres-
ence of all three genetic mutations was associated with an
OR of 125.8.
This study is a hypothesis-generating study, designed
to examine the association between the different genetic
mutations and graft failure. The data are fairly preliminary
but seem to point to an important role of the MTHFR gene
in postreconstruction graft failure. Widespread screening
for the gene cannot be recommended until a larger scale
study confirms these findings.
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